Status and phase
Conditions
Treatments
About
To evaluate the combination of telbivudine 600 mg orally (PO) once daily and peginterferon alpha-2a 180 ug subcutaneous (sq) injection weekly for antiviral efficacy in comparison to peginterferon alpha-2a monotherapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Documented Chronic hepatitis B (CHB) defined by all of the following:
Exclusion criteria
Co-infection with Hepatitis C Virus (HCV), Hepatitis D Virus (HDV), or Human Immunodeficiency Virus (HIV).
Has any of the following drug therapy:
Patient has any of the following:
Has laboratory values during screening visit not within normal limits.
Is pregnant or breastfeeding.
Is a women of child-bearing potential that is unwilling to practice birth control.
Primary purpose
Allocation
Interventional model
Masking
159 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal